|
|
|
Volumn 56, Issue 4, 2008, Pages 309-315
|
|
Paradigm shift in the treatment of rheumatoid arthritis by biologics
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIRHEUMATIC AGENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
METHOTREXATE;
MONOCLONAL ANTIBODY;
RITUXIMAB;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG DESIGN;
HUMAN;
INFLAMMATION;
PHYSIOLOGY;
REVIEW;
RHEUMATOID ARTHRITIS;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
HUMANS;
IMMUNOGLOBULIN G;
INFLAMMATION;
METHOTREXATE;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 47749090969
PISSN: 00471860
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (1)
|
|
References (20)
|
